Biblio

Author Title Type [ Year

]

Filters: Author is Ho, Anthony D [Clear All Filters]

2023

Linke P, Munding N, Kimmle E, Kaufmann S, Hayashi K, Nakahata M, Takashima Y, Sano M, Bastmeyer M, Holstein T, et al. Reversible Host-Guest Crosslinks in Supramolecular Hydrogels for On-Demand Mechanical Stimulation of Human Mesenchymal Stem Cells. Adv Healthc Mater. 2023:e2302607.

Schubert M-L, Schmitt A, Hückelhoven-Krauss A, Neuber B, Kunz A, Waldhoff P, Vonficht D, Yousefian S, Jopp-Saile L, Wang L, et al. Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial. J Hematol Oncol. 2023;16(1):79.

2021

Saeed BR, Manta L, Raffel S, Pyl PTheodor, Buss EC, Wang W, Eckstein V, Jauch A, Trumpp A, Huber W, et al. Analysis of non-leukemic cellular subcompartments reconstructs clonal evolution of acute myeloid leukemia and identifies therapy-resistant pre-leukemic clones. Int J Cancer. 2021.

2020

Schuber M-L, Dietrich S, Stilgenbauer S, Schmitt A, Pavel P, Kunz A, Bondong A, Wegner M, Stadtherr P, Jung S, et al. Feasibility and safety of CD19 CAR T cell treatment for B-cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020.

2018

Ohta T, Monzel C, Becker AS, Ho AD, Tanaka M. Simple Physical Model Unravels Influences of Chemokine on Shape Deformation and Migration of Human Hematopoietic Stem Cells. Sci Rep. 2018;8(1):10630.

2016

Schubert M-L, Hückelhoven AGabriele, Hoffmann J-M, Schmitt A, Wuchter P, Sellner L, Hofmann S, Ho AD, Dreger P, Schmitt M. Chimeric antigen receptor (CAR) T cell therapy targeting CD19 positive leukemia and lymphoma in the context of stem cell transplantation. Hum Gene Ther. 2016.

Lisenko K, Cremer M, Schwarzbich M-A, Kriegsmann M, Ho AD, Witzens-Harig M, Wuchter P. Efficient stem cell collection after modified cisplatin-based mobilization chemotherapy in patients with DLBCL. Biol Blood Marrow Transplant. 2016.

Schmitt M, Hückelhoven AG, Hundemer M, Schmitt A, Lipp S, Emde M, Salwender H, Hänel M, Weisel K, Bertsch U, et al. Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial. Oncotarget. 2016.

Krämer I, Engelhardt M, Fichtner S, Neuber B, Medenhoff S, Bertsch U, Hillengass J, Raab M-S, Hose D, Ho AD, et al. Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro. Oncoimmunology. 2016;5(5):e1139662.

2015

Lisenko K, Stadtherr P, Bruckner T, Pavel P, Heilig C, Schmitt A, Puthenparambil J, Brandt J, Ho AD, Dreger P, et al. Bone marrow harvesting of allogeneic donors in an outpatient setting: a single-center experience. Biol Blood Marrow Transplant. 2015.

Stiehl T, Baran N, Ho AD, Marciniak-Czochra A. Cell division patterns in acute myeloid leukemia stem-like cells determine clinical course: a model to predict patient survival. Cancer Res. 2015.

Casalegno-Garduño R, Schmitt A, Spitschak A, Greiner J, Wang L, Hilgendorf I, Hirt C, Ho AD, Freund M, Schmitt M. Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation. Int J Cancer. 2015.

Radujkovic A, Becker N, Benner A, Penack O, Platzbecker U, Stölzel F, Bornhäuser M, Hegenbart U, Ho AD, Dreger P, et al. Pre-transplant weight loss predicts inferior outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndrome. Oncotarget. 2015.

2014

Schmitt T, Goldschmidt H, Neben K, Freiberger A, Hüsing J, Gronkowski M, Thalheimer M, Pelzl LHang, Mikus G, Burhenne J, et al. Aprepitant, Granisetron, and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting After High-Dose Melphalan in Autologous Transplantation for Multiple Myeloma: Results of a Randomized, Placebo-Controlled Phase III Trial. J Clin Oncol. 2014.

Stiehl T, Ho AD, Marciniak-Czochra A. Assessing Hematopoietic (Stem-) Cell Behavior During Regenerative Pressure. Adv Exp Med Biol. 2014;844:347-367.

Radujkovic A, Luft T, Dreger P, Ho AD, W Zeller J, Fruehauf S, Topaly J. In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemia. Cancer Chemother Pharmacol. 2014.

Nicolay NH, Sommer E, Perez RLopez, Wirkner U, Bostel T, Ho AD, Lahn M, Debus J, Saffrich R, Huber PE. Mesenchymal stem cells are sensitive to treatment with kinase inhibitors and ionizing radiation. Strahlenther Onkol. 2014.

Dietrich S, Radujkovic A, Stölzel F, Falk CS, Benner A, Schaich M, Bornhäuser M, Ehninger G, Krämer A, Hegenbart U, et al. Pretransplant Metabolic Distress Predicts Relapse of Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation. Transplantation. 2014.

Rachakonda SP, Penack O, Dietrich S, Blau O, Blau IWolfgang, Radujkovic A, Isermann B, Ho AD, Uharek L, Dreger P, et al. Single-Nucleotide Polymorphisms Within the Thrombomodulin Gene (THBD) Predict Mortality in Patients With Graft-Versus-Host Disease. J Clin Oncol. 2014.

2013

Dietrich S, Okun JG, Schmidt K, Falk CS, Wagner AH, Karamustafa S, Radujkovic A, Hegenbart U, Ho AD, Dreger P, et al. High pre-transplant serum nitrate levels predict risk of acute steroid-refractory graft-versus-host disease in the absence of statins. Haematologica. 2013.

Schaich M, Parmentier S, Kramer M, Illmer T, Stölzel F, Röllig C, Thiede C, Hänel M, Schäfer-Eckart K, Aulitzky W, et al. High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute Myeloid Leukemia: Results of the Prospective Randomized AML2003 Trial. J Clin Oncol. 2013.

Hoang VT, Hoffmann I, Borowski K, Zepeda-Moreno A, Ran D, Buss EC, Wuchter P, Eckstein V, Ho AD. Identification and separation of normal hematopoietic stem cells and leukemia stem cells from patients with acute myeloid leukemia. Methods Mol Biol. 2013;1035:217-30.